-
公开(公告)号：US20180258146A1
公开(公告)日：2018-09-13
申请号：US15973715
申请日：2018-05-08
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： Normand BLAIS , Philippe Marc Helene DEHOTTAY , Marianne DEWERCHIN , Philippe GOFFIN , Denis MARTIN
CPC classification number: C07K14/34 , C07K1/00 , C07K2319/034 , C12N9/1077 , C12Y204/02036
Abstract: Methods for producing a conjugate of a bacterial toxin, including diphtheria toxin or CRM197, are provided.
-
公开(公告)号：US20180243368A1
公开(公告)日：2018-08-30
申请号：US15957445
申请日：2018-04-19
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Jill Wykosky , Denise Mazess Herpai
CPC classification number: A61K38/177 , A61K38/00 , A61K38/2086 , A61K38/45 , A61K45/06 , A61K47/64 , A61K47/642 , A61K47/6801 , A61K49/0002 , C07K14/52 , C07K14/705 , C12Y204/02036
Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
-
公开(公告)号：US09873743B2
公开(公告)日：2018-01-23
申请号：US15342668
申请日：2016-11-03
Applicant: Stemline Therapeutics, Inc.
Inventor： Ivan Bergstein
IPC: C12P21/02 , C07K16/28 , C12N9/10 , C12P21/06 , C12N15/64 , C12N5/16 , C07K14/705 , A61K39/395
CPC classification number: C07K16/2866 , A61K39/00 , C07K16/18 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/55 , C12N5/163 , C12N9/1048 , C12N9/1077 , C12N15/86 , C12Y204/02036
Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.
-
公开(公告)号：US20170281736A1
公开(公告)日：2017-10-05
申请号：US15616140
申请日：2017-06-07
Applicant: Applied Molecular Transport, LLC
Inventor： Randall Mrsny , Tahir Mahmood
CPC classification number: A61K38/45 , A61K38/1793 , A61K38/20 , A61K38/2066 , A61K38/26 , A61K38/27 , C07K16/241 , C07K2317/76 , C07K2319/21 , C07K2319/30 , C07K2319/32 , C07K2319/50 , C07K2319/55 , C07K2319/60 , C07K2319/90 , C12Y204/02036
Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.
-
公开(公告)号：US09764006B2
公开(公告)日：2017-09-19
申请号：US14650699
申请日：2013-12-09
Applicant: The General Hospital Corporation
Inventor： Zhirui Wang , Christene A. Huang , David H. Sachs
IPC: C07K14/55 , C12N15/09 , C12N15/63 , A61K38/20 , A61K38/45 , A61K45/06 , C12N15/81 , C12N9/10 , C07K14/21 , A61K38/00
CPC classification number: A61K38/45 , A61K38/00 , A61K38/2013 , A61K45/06 , C07K14/21 , C07K14/55 , C07K2319/55 , C12N9/1077 , C12N15/09 , C12N15/63 , C12N15/815 , C12Y204/02036 , A61K2300/00
Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.
-
Patent Agency Ranking
公开(公告)号：US20170232115A1
公开(公告)日：2017-08-17
申请号：US15380962
申请日：2016-12-15
Applicant: STC.UNM , Sandia Corporation
Inventor： Carlee Erin Ashley , C. Jeffrey Brinker , Eric C. Carnes , Mohammed Houman Fekrazad , Linda A. Felton , Oscar Negrete , David Patrick Padilla , Brian S. Wilkinson , Dan C. Wilkinson , Cheryl L. Willman
IPC: A61K49/00 , A61K33/24 , A61K31/513 , C12N15/113 , A61K38/45 , A61K31/506 , A61K38/47 , A61K31/465 , A61K31/192 , A61K31/704 , A61K48/00
CPC classification number: A61K48/0008 , A61K9/0014 , A61K9/107 , A61K9/1271 , A61K9/5078 , A61K31/192 , A61K31/465 , A61K31/506 , A61K31/513 , A61K31/704 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K33/24 , A61K38/00 , A61K38/17 , A61K38/45 , A61K38/47 , A61K45/06 , A61K47/6923 , A61K49/0082 , A61K49/0423 , B82Y5/00 , C07K7/06 , C07K2319/00 , C12N15/113 , C12N15/1131 , C12N15/88 , C12N2310/14 , C12N2320/32 , C12N2810/40 , C12Y204/02036 , C12Y302/02022 , A61K2300/00
Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.
-
公开(公告)号：US20170152321A1
公开(公告)日：2017-06-01
申请号：US15342668
申请日：2016-11-03
Applicant: Stemline Therapeutics, Inc.
Inventor： Ivan Bergstein
CPC classification number: C07K16/2866 , A61K39/00 , C07K16/18 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/55 , C12N5/163 , C12N9/1048 , C12N9/1077 , C12N15/86 , C12Y204/02036
Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.
-
公开(公告)号：US20170137513A1
公开(公告)日：2017-05-18
申请号：US15187579
申请日：2016-06-20
Applicant: Daniel A. Vallera , Jeff Lion
Inventor： Daniel A. Vallera , Jeff Lion
CPC classification number: C07K16/2803 , A61K38/00 , A61K38/164 , A61K38/19 , A61K47/6827 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K14/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/55 , C12N9/1077 , C12Y204/02036
Abstract: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.
-
公开(公告)号：US20170037386A1
公开(公告)日：2017-02-09
申请号：US15234297
申请日：2016-08-11
Applicant: Intrexon Corporation
Inventor： Timothy David Jones , Francis Joseph Carr
IPC: C12N9/10
CPC classification number: C12N9/1077 , A61K38/00 , A61K39/00 , A61K39/02 , C07K14/21 , C07K16/2803 , C07K2317/622 , C12Y204/02036
Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
Abstract translation: 假单胞菌外毒素A或“PE”是由铜绿假单胞菌分泌的66kD，高效的细胞毒性蛋白质。 已经将各种形式的PE偶联到其它蛋白质，例如抗体，以产生选择性靶向所需表型细胞（例如肿瘤细胞）的治疗上有用的细胞毒素缀合物。 在本发明中，分析跨越约38kD形式的假单胞菌外毒素A蛋白的序列的免疫原性CD4 + T细胞表位的存在。 鉴定了6种免疫原性T细胞表位。 在每个表位内鉴定出残基，用于引入靶向氨基酸取代，以减少或预防可能施用于异源宿主的PE分子中的免疫原性T细胞应答。
-
10.发明授权Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses 有权用作诱导抗原特异性T细胞应答的免疫原性增强子的融合蛋白公开(公告)号：US09481714B2
公开(公告)日：2016-11-01
申请号：US14095760
申请日：2013-12-03
Applicant: TheVax Genetics Vaccine Co., Ltd.
Inventor： Chia-Mao Wu , Hsiu-Kang Chang
IPC: A61K39/00 , C07K14/005 , A61K39/21 , A61K47/48 , A61K39/385 , C07K14/705 , A61K39/12 , A61K39/135 , A61K39/17 , C07K14/81 , C12N9/10 , C12N9/14 , C07K14/21
CPC classification number: C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
Abstract translation: 公开了用作增强抗原特异性T细胞应答的免疫原增强剂的融合蛋白。 融合蛋白包括：（a）抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）蛋白转导结构域; 和（c）病原体的抗原，其中APC结合结构域或CD91受体结合结构域位于融合蛋白的N末端，并且病原体的抗原位于 蛋白转导结构域。 蛋白转导结构域选自：（i）包含T细胞致敏信号转导肽，接头和易位肽的融合多肽; （ii）T细胞增感信号转导肽; 和（iii）长度为34-112个氨基酸残基的易位肽。
-
-
-
-
-
-
-
-
-
Search Results
114
records
(took 0.054 seconds)
